CoChat

Saroglitazar, a Dual PPAR α/γ Agonist, Improves Atherogenic Dyslipidemia in Patients With Non-Cirrhotic Nonalcoholic Fatty Liver Disease: A Pooled Analysis

Siddiqui, Mohammad Shadab, Parmar, Deven, Sheikh, Farheen, Sarin, Shiv Kumar, Cisneros, Laura, Gawrieh, Samer, Momin, Taufik, Duseja, Ajay, Sanyal, Arun J. · 2023 · Clinical Gastroenterology and Hepatology
Cited by 42

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Abstract

BACKGROUND AND AIMS Cardiovascular disease is the leading cause of mortality in NAFLD. The aim of this study was to evaluate the effects of saroglitazar, a dual PPAR α/γ agonist, on serum lipids in patients with NAFLD METHODS: A total of 221 patients (Saroglitazar [130], placebo [91]) with NAFLD from phase 2 and 3 double blinded placebo-controlled randomized clinical trials were pooled to assess the impact of saroglitazar magnesium 4 mg on traditional lipids, very low density lipoprotein cholesterol (VLDL-C), and small dense LDL-C (sdLDL-C). Change from baseline in lipid parameters was performed using analysis of covariance including treatment as fixed effect, and baseline value, diabetes, hypertension and statin use as covariates. RESULTS Treatment with saroglitazar significantly improved total cholesterol (-17 mg/dL, 95% CI -24, 9, p<0.001), triglyceride (-45 mg/dL, 95% CI -60, 31, p<0.001), LDL-C (-8 mg/dL, 95% CI -15, -1, p=0.01), and VLDL-C (-8 mg/dL, -14, -3, p<0.001). Saroglitazar improved serum lipids as early as 4-6 weeks of initiation of therapy and these effects persisted for duration of therapy. Saroglitazar also improved the highly atherogenic sdLDL-C (-10 mg/dL, -17, -2, p=0.01). In subgroup analysis of patients with either diabetes or hypertension, saroglitazar significantly improved serum lipids. CONCLUSION Saroglitazar improved the serum atherogenic lipoprotein profile in patients with NAFLD, irrespective of co-morbid conditions and statin use. Saroglitazar has the potential to not only positively affect liver disease but also reduce cardiovascular risk in patients with NAFLD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.cgh.2023.01.018

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 42

Metadata

Authors
Siddiqui, M. S., Parmar, D., Sheikh, F., Sarin, S. K., Cisneros, L., Gawrieh, S., Momin, T., Duseja, A., & Sanyal, A. J.
Venue
Clinical Gastroenterology and Hepatology
Publisher
Elsevier BV
Published
2023-09
Volume
21
Issue
10
Pages
2597-2605.e2
ISSN
1542-3565 (ISSN-L)
OpenAlex
W4318561977
Cited by
42
References
11
FWCI
7.02
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.